公开(公告)号：EP2958587A1

公开(公告)日：2015-12-30

申请号：EP14706057.8

申请日：2014-02-25

申请人： Klinikum rechts der Isar der Technischen Universität München ,  Technische Universität München ,  Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

发明人： KNOLLE, Percy ,  HEIKENWÄLDER, Mathias ,  PROTZER, Ulrike ,  HUANG, Li-Rung

IPC分类号： A61K39/39

CPC分类号： A61K39/292 ,  A61K39/39 ,  A61K2039/525 ,  C12N7/00 ,  C12N2730/10134 ,  C12N2730/10171

摘要： In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.

公开(公告)号：EP2958587B1

公开(公告)日：2018-11-21

申请号：EP14706057.8

申请日：2014-02-25

申请人： Klinikum rechts der Isar der Technischen Universität München ,  Technische Universität München ,  Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

发明人： KNOLLE, Percy ,  HEIKENWÄLDER, Mathias ,  PROTZER, Ulrike ,  HUANG, Li-Rung

IPC分类号： A61K39/39

CPC分类号： A61K39/292 ,  A61K39/39 ,  A61K2039/525 ,  C12N7/00 ,  C12N2730/10134 ,  C12N2730/10171

摘要： In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.